Non-invasive prenatal paternity testing (NIPAT) relies on detecting cell-free fetal DNA (cffDNA) in maternal plasma. Traditional approaches based on single nucleotide polymorphisms (SNPs) face challenges due to low fetal DNA fractions and sequencing errors. To improve accuracy, we developed NEWPAT, a novel method using double nucleotide polymorphisms (DNPs), genetic markers where two consecutive nucleotide changes occur on the same haplotype. DNPs are strictly biallelic, existing in only two haplotypic forms, which reduces the possibility of sequencing errors being misinterpreted as true variants. The probability of both bases being miscalled simultaneously is extremely low, making DNPs highly reliable for paternal allele detection. We selected 925 genome-wide DNPs on autosomes and X chromosome from the Genome Aggregation Database. Target enrichment was performed using the Ion AmpliSeq™ Kit Plus, and ultra-deep sequencing was conducted on the Ion Torrent™ S5 platform. Validation encompassed 42 individuals analyzed across four batches: 1) 15 individuals from 4 families sequenced at 5,000× to assess Mendelism and DNP amplification bias; 2) two artificial mixtures mimicking cffDNA; 3) 12 pregnant women sequenced at 10,000× and fathers at 1,000× to evaluate system reliability and paternity index estimation; and 4) 3 unrelated males as external controls. NEWPAT reliably detected cffDNA even at very low concentration (<<1%). In all pregnancies, CPI exceeded 10³⁵, far surpassing the standard threshold for paternity attribution. These results confirm the accuracy of DNP-based detection, establishing NEWPAT as a key advancement in prenatal paternity testing by improving fetal fraction estimation, reducing errors, and enhancing sequencing efficiency for forensic use.
NEWPAT: Development of a highly specific non-invasive prenatal paternity test using DNP markers / Pistacchia, L.. - (2025). (XXX CONGRESSO NAZIONALE Ge.F.I. “New directions in forensic genetics” Università Cattolica del Sacro Cuore di Roma, Roma, Italia ).
NEWPAT: Development of a highly specific non-invasive prenatal paternity test using DNP markers
Letizia Pistacchia
2025
Abstract
Non-invasive prenatal paternity testing (NIPAT) relies on detecting cell-free fetal DNA (cffDNA) in maternal plasma. Traditional approaches based on single nucleotide polymorphisms (SNPs) face challenges due to low fetal DNA fractions and sequencing errors. To improve accuracy, we developed NEWPAT, a novel method using double nucleotide polymorphisms (DNPs), genetic markers where two consecutive nucleotide changes occur on the same haplotype. DNPs are strictly biallelic, existing in only two haplotypic forms, which reduces the possibility of sequencing errors being misinterpreted as true variants. The probability of both bases being miscalled simultaneously is extremely low, making DNPs highly reliable for paternal allele detection. We selected 925 genome-wide DNPs on autosomes and X chromosome from the Genome Aggregation Database. Target enrichment was performed using the Ion AmpliSeq™ Kit Plus, and ultra-deep sequencing was conducted on the Ion Torrent™ S5 platform. Validation encompassed 42 individuals analyzed across four batches: 1) 15 individuals from 4 families sequenced at 5,000× to assess Mendelism and DNP amplification bias; 2) two artificial mixtures mimicking cffDNA; 3) 12 pregnant women sequenced at 10,000× and fathers at 1,000× to evaluate system reliability and paternity index estimation; and 4) 3 unrelated males as external controls. NEWPAT reliably detected cffDNA even at very low concentration (<<1%). In all pregnancies, CPI exceeded 10³⁵, far surpassing the standard threshold for paternity attribution. These results confirm the accuracy of DNP-based detection, establishing NEWPAT as a key advancement in prenatal paternity testing by improving fetal fraction estimation, reducing errors, and enhancing sequencing efficiency for forensic use.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


